Fulton Bank N.A. trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 10.3% in the first quarter, Holdings Channel reports. The institutional investor owned 40,758 shares of the company’s stock after selling 4,664 shares during the quarter. Fulton Bank N.A.’s holdings in Merck & Co., Inc. were worth $3,390,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. PRW Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $41,000. Aspire Private Capital LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $55,000. Financial Gravity Companies Inc. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $66,000. Mark Sheptoff Financial Planning LLC raised its holdings in shares of Merck & Co., Inc. by 150.0% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the company’s stock valued at $76,000 after buying an additional 600 shares during the last quarter. Finally, Vestor Capital LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $77,000. 75.17% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently issued reports on MRK. Goldman Sachs Group initiated coverage on Merck & Co., Inc. in a report on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 price target for the company. Bank of America boosted their price objective on Merck & Co., Inc. from $90.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. BMO Capital Markets reissued a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, February 19th. Argus boosted their price objective on Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 20th. Finally, ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $83.08.
Shares of NYSE:MRK opened at $82.90 on Friday. The stock has a market cap of $213.64 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 1.97 and a beta of 0.55. Merck & Co., Inc. has a 1-year low of $59.80 and a 1-year high of $84.27. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.17. The firm had revenue of $10.82 billion during the quarter, compared to analysts’ expectations of $10.45 billion. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.05 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 4.72 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $2.20 annualized dividend and a dividend yield of 2.65%. Merck & Co., Inc.’s payout ratio is currently 50.69%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: Beta
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.